No headlines found.
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period
Globe Newswire (Thu, 16-Jul 4:30 PM ET)
Cellyan Biotechnology Co Ltd is an integrated pharmaceutical cross-border e-commerce supply chain service provider with a professional team and related pharmaceutical storage facilities in Hong Kong. It operates through two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, referred to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, referred to as the Procurement and Distribution division. Its main business provides one-stop services for merchants engaged in cross-border pharmaceutical e-commerce, including OTC wholesale, import and export, warehousing, packaging, customs clearance and delivery to final destinations, forming a closed loop of pharmaceutical cross-border e-commerce supply chain.
Cellyan Biotechnology Co. - Class A trades on the NASDAQ stock market under the symbol HKPD.
As of September 4, 2026, HKPD stock price declined to $0.13 with 1,866,172 million shares trading.
HKPD has a beta of 1.52, meaning it tends to be more sensitive to market movements. HKPD has a correlation of 0.02 to the broad based SPY ETF.
HKPD has a market cap of $3.00 million. This is considered a Sub-Micro Cap stock.
HKPD has underperformed the market in the last year with a price return of -87.7% while the SPY ETF gained +19.8%. HKPD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -74.7% and -68.8%, respectively, while the SPY returned +2.0% and +0.6%, respectively.
HKPD support price is $.13 and resistance is $.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HKPD shares will trade within this expected range on the day.
